A Phase IIa, Open Label Study to Determine the Early Bactericidal,Extended Early Bactericidal Activity and Pharmacokinetic Study of LL 3858 of Lupin Limited for the Treatment of Newly Diagnosed Sputum Smear-Positive Pulmonary Tuberculosis.

Start Date02 Dec 2009

Sponsor / Collaborator-

100 Clinical Results associated with Sudoterb

100 Translational Medicine associated with Sudoterb

100 Patents (Medical) associated with Sudoterb

Literatures (Medical) associated with Sudoterb

01 Aug 2020·European Journal of Pharmaceutical SciencesQ2 · MEDICINE

Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis

Q2 · MEDICINE

Review

Author: Vargas-Méndez, Leonor Yamile ; Kouznetsov, Vladimir V ; Villamizar-Mogotocoro, Andrés-Felipe

Tuberculosis (TB) disease remains to be an alarming infection worldwide with nearly 1.6 million deaths per year ranking above HIV/AIDS. Although Mycobacterium tuberculosis (Mtb), which causes TB, was identified more than 130 years ago, nowadays only old vaccine (Bacillus Calmette-Guérin vaccine) and classical toxic drugs that are losing its effectiveness are available in clinic practice. Despite enormous efforts in drug research on TB treatment including vaccines and diagnostics investigations, this old contagious, infectious disease is still a major public health problem. The goal of elimination of epidemic TB disease by 2035 will not be achieved without combined strategies based on faster diagnostic tools, effective vaccines and drugs. In the field of TB chemotherapy, novel molecular design of new compounds able to efficiently kill Mtb via a disruption of new diverse biological targets is evidently required. In this sense, pyridine and quinoline compounds stand out as promising molecules against drug-resistant tuberculosis. Indeed, many candidate drugs based on heterocyclic skeletons are currently being tested. Among them, quinoline derivatives like gatifloxacin, moxifloxacin and bedaquiline (sirturo), and pyridine molecules such as sudoterb and agent BRD-8000.3 have been shown to have high potential for more effective treatment of the drug-resistant forms of TB disease. In this work we review the most significant advances in the design of such molecules discussing briefly their physicochemical parameters (descriptors) calculated by available Molinspiration software.

01 Jun 2017·European Journal of Medicinal ChemistryQ1 · MEDICINE

Isoniazid derivatives and their anti-tubercular activity

Q1 · MEDICINE

Review

Author: Lv, Zao-Sheng ; Zhang, Shu ; Wu, Xiang ; Gao, Chuan ; Zhao, Feng ; Xu, Zhi ; Hu, Yuan-Qiang ; Feng, Lian-Shun

Tuberculosis (TB), which has been a scourge of humanity for thousands of years, is a worldwide pandemic disease caused mainly by Mycobacterium tuberculosis (MTB). The emergence of drug-resistant TB (DR-TB), multidrug-resistant TB (MDR-TB), extensively drug-resistant TB (XDR-TB) and totally drug-resistant TB (TDR-TB) increase the challenges to eliminate TB worldwide. Isoniazid (INH), a critical frontline anti-TB drug, is one of the most effective drugs used to treatment of TB infection for more than 60 years. Unfortunately, bacterial strains resistant to INH are becoming common which mainly due to the long-term widely use even abuse. Therefore, there is an urgent need to develop novel anti-TB agents. Numerous efforts have been undertaken to develop new anti-TB agents, but no new drug has been introduced for more than 5 decades. It has been suggested that the incorporation of lipophilic moieties into the framework of INH can increase permeation of the drug into bacterial cells, thereby enhancing the anti-TB. Therefore, INH derivatives with greater lipophilicity are emerging as one of the most potential anti-TB agents. Indeed, the INH derivative LL-3858 is in initial stages of phase II clinical trial for the treatment of TB and may be approved to treat TB in the near future. This review aims to summarize the recent advances made towards the discovery anti-TB agents holding INH as a nucleus including INH hybrids and INH hydrazide-hydrazone derivatives.

20 Feb 2017·Mini-Reviews in Medicinal ChemistryQ3 · MEDICINE

Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches

Q3 · MEDICINE

Review

Author: Tandon, Rashmi ; Nath, Mahendra

Tuberculosis is very much rampant in our society and accounts for a large number of deaths annually. In spite of consistent efforts being made, the disease has not been curtailed yet. The emergence of MDR and XDR strains in the society along with an increase in the number of HIV cases and that of latent TB, have further aggravated the problem making the disease very much persistent. The current situation clearly manifests the need to discover and develop new potent molecules/approaches that could help to tackle drug resistance. Various molecules, such as derivatives of fluoroquinolones (e.g. gatifloxacin, moxifloxacin and DC-159a), rifamycins (rifapentine), oxazolidinones (linezolid, sutezolid/PNU-100480), diarylquinolines (TMC207/bedaquiline), antifungal azoles, pyrrole (LL3858), nitroimidazopyran (PA824), nitroimidazole (OPC67683, TBA-354), diamine (SQ109) and benzothiazinone (BTZ043) are being developed in an attempt to combat the disease. This review presents a general introduction to the current status of the disease, the biology of the pathogen as well as the state of drug development against tuberculosis (TB) with emphasis on the major problems and bottlenecks associated with the same. Starting from the first drug against TB, the review discusses the entire history and the course of development of the drugs which are available today in the market as well as those which are under various phases of clinical and pre-clinical trials along with their mechanism of action. It also talks about the possible role of nanosciences in combating TB.

100 Deals associated with Sudoterb

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Tuberculosis	Phase 2	-	Lupin Ltd	-
Tuberculosis	Phase 2	IN	Lupin Ltd	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Sudoterb

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation